Response to review by Pan et al.

The author of this letter is responding to a meta-analysis on the efficacy and safety of various antiobesity medications, specifically focusing on orlistat. The author questions the findings of the meta-analysis, which reported that orlistat had the highest risk for adverse events and severe adverse events compared to other medications. The author argues that previous meta-analyses did not find such high risks associated with orlistat and provides examples of clinical trials that could have been included in the analysis. The author also discloses their conflict of interest as they have equity interests in a pharmaceutical company and hold a patent for a weight loss product that includes orlistat. [Extracted from the article]